<DOC>
	<DOCNO>NCT00903188</DOCNO>
	<brief_summary>This study intend determine whether steroid withdrawal calcineurin inhibitor withdrawal superior graft function graft survival . Secondary endpoint study : incidence tumor cardiovascular event . The primary objective : To assess superior graft function ( glomerular filtration rate ( GFR ) difference 10 ml/min ) achieve 1 year transplantation cohort de novo kidney transplant patient treat Myfortic-everolimus plus steroid compare Myfortic-cyclosporine .</brief_summary>
	<brief_title>Calcineurin Inhibitor ( CNI ) Versus Steroid Cessation Renal Transplantation</brief_title>
	<detailed_description>Methodology : - A 5-year , multicentre , prospective , randomize , open-label , control study - Group 1 : Simulect + cyclosporine + Myfortic + steroid stop 3 month - Group 2 : Simulect + cyclosporine ( decrease dose one week month 3 replace everolimus ) + Myfortic + steroid maintenance . - In group MPA AUC monitor do 5-7 day 3 month , ensure sufficient MPA protection . Sample size calculation : A total 152 patient randomize ( 76 patient per group ) Population : De novo kidney transplant recipient . Study duration : 1.5 year inclusion+ follow-up first 5 year</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Male female recipient de novo kidney transplant , age 18 year Women childbearing potential must negative serum urine pregnancy test sensitivity equal least 50 mIU/ml Patients must capable understand purpose risk study , must sign informed consent form Multiple organ transplantation ( e.g. , Kidneypancreas , kidneyheart , kidney liver , ... ) Transplantation patient get another organ transplant previously Recipients HLAidentical livingrelated renal transplant Patients PRA &gt; 30 % , patient lose first graft rejection within two year transplantation , African European patient . Patients primary renal disease risk recurrence : FSGS , MPGN , HUS Pregnant lactate woman WBC &lt; 2.5 x 109/l ( IU ) , platelet count &lt; 100 x 109/l ( IU ) , Hb &lt; 6 g/dl time entry study Active peptic ulcer Severe diarrhea gastrointestinal disorder , might interfere ability absorb oral medication , include diabetic patient previously diagnose diabetic gastroenteropathy Known HIV1 HTLV1 positive test The use investigational drug immunosuppressive drug , specify protocol Patients receive bile acid sequestrants Psychological illness condition , interfere patient 's compliance ability understand requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Renal Transplantation</keyword>
	<keyword>graft function</keyword>
	<keyword>cardiovascular event</keyword>
	<keyword>malignancy</keyword>
	<keyword>cyclosporin</keyword>
	<keyword>steroid</keyword>
	<keyword>mycophenolate</keyword>
	<keyword>everolimus</keyword>
	<keyword>renal biopsy</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>